By Kailyn Rhone
Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration.
The new drug application for the treatment in adults combines two drugs, avutometinib and defactinib.
The FDA's decision is expected by June 30, 2025. If approved, it would be the first treatment specifically for this type of cancer, the company said.
"We're taking an important step forward in addressing a condition that has long been overlooked," said Dan Paterson, president and chief executive officer of Verastem Oncology, "We look forward to working with the FDA during its review process and preparing for a commercial launch in mid-2025."
Shares soared 21% after hours to $4.46. For the year, shares are down by more than 50 percent.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
December 30, 2024 17:20 ET (22:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。